Related Experiment Video
Updated: Jun 6, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Recent progress in antithrombotic therapy for atrial fibrillation
Selvakumar Velu1, Gregory Y H Lip
1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Journal of Atherosclerosis and Thrombosis
|November 20, 2010
Summary
Atrial fibrillation (AF) increases stroke risk, but warfarin use is limited. Newer anticoagulants offer improved alternatives for preventing thromboembolism in AF patients.
Area of Science:
- Cardiology
- Pharmacology
- Geriatric Medicine
Background:
- Atrial fibrillation (AF) poses a significant and growing healthcare challenge, particularly with aging populations.
- Patients with AF face a heightened risk of stroke and thromboembolism, necessitating effective thromboprophylaxis.
- Adjusted-dose warfarin is a proven anticoagulant for stroke risk reduction in AF, outperforming antiplatelet agents.
Purpose of the Study:
- To review recent advancements in thromboprophylaxis for atrial fibrillation.
- To discuss the challenges and future directions of anticoagulation therapies for AF.
- To highlight efforts in developing safer and more convenient alternatives to warfarin.
Main Methods:
- Literature review of recent studies and clinical trials.
- Analysis of current guidelines and epidemiological data on AF.
- Evaluation of novel anticoagulant agents and risk stratification tools.
Main Results:
- Warfarin, while effective, has limitations leading to suboptimal use.
- Newer anticoagulants are being developed with comparable or superior efficacy and improved usability.
- Enhanced risk stratification models aim to better predict thromboembolic events in AF patients.
Conclusions:
- Despite warfarin's efficacy, suboptimal anticoagulation remains an issue in AF management.
- Ongoing research focuses on developing superior anticoagulation strategies for AF.
- Future therapeutic approaches aim to balance efficacy, safety, and patient convenience.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...